Get started
JUBILANT PHARMOVA LTDJUBILANT PHARMOVA LTDJUBILANT PHARMOVA LTD

JUBILANT PHARMOVA LTD

No trades
See on Supercharts
Overview Financials News
Ideas
Discussions Technicals Forecast Seasonals

JUBLPHARMA trade ideas

Jubilant Pharmova Limited - Bullish on Chart📊 Script: JUBLPHARMA (JUBILANT PHARMOVA LIMITED) 📊 Nifty50 Stock: NO 📊 Sectoral Index: N/A 📊 Sector: Healthcare 📊 Industry: Pharmaceuticals Key highlights: 💡⚡ 📈 Script is trading at upper band of Bollinger Bands (BB) and giving breakout of it. 📈 MACD is giving crossover. 📈 Double Moving Averages also giving crossover. 📈 Volume is increasing along with price which is volume breakout. 📈 Current RSI is around 69. 📈 One can go for Swing Trade. ⏱️ C.M.P 📑💰- 370 🟢 Target 🎯🏆 - 450 ⚠️ Stoploss ☠️🚫 - 329 ⚠️ Important: Always maintain your Risk & Reward Ratio. ⚠️ Purely technical based pick. ✅Like and follow to never miss a new idea!✅ Disclaimer: I am not SEBI Registered Advisor. My posts are purely for training and educational purposes. Eat🍜 Sleep😴 TradingView📈 Repeat🔁 Happy Labh Pancham 🪔🎉✨ Happy learning with trading. Cheers!🥂
NSE:JUBLPHARMALong
by radha_23
2
JUBLIANT PHARMA Levels, swing posed for an upmove of 20% 1) Monthly - Reversing from Previous low after a proper Double bottom Reversal Pattern. RSI perfectly moving from oversold to strength of 60+. Mid term investors may look to accumulate at the demand zones with Previous low 270 region as SL for a target of 625+. 2) Weekly shows a good breakout breaking out of an 8 months old stiff resistance, after having consolidated for solid 7 weeks. 3) As the daily RSI is in overbought zone, one may consider buying at the retest of the trendline breakout at 420 zone or the demand areas marked in green. Demand zones - Green zone. Supply zones - Black zone.
NSE:JUBLPHARMALong
by Rugminik
jublipharmaPharmaceutical maker Jubilant Pharmova, wholly owned subsidiary Jubilant Pharma Limited, through one of its wholly owned subsidiaries, Jubilant HollisterStier General Partnership, will invest $76.6 million to expand capacity at its Contract Manufacturing Organization (CMO) Montreal, Canada facility. Jubilant will receive a more than $19 million loan from the Government of Quebec through its agent Investissement Quebec, including a forgivable portion of nearly $5 million. “Jubilant HollisterStier is chosen as a part of the eco-system being developed by Canada to make it self-dependent for its future needs of vaccines and treatments in case of a pandemic
NSE:JUBLPHARMALong
by Tradernawab
JUBLPHARMANSE:JUBLPHARMA Please note that we are not a SEBI Registered Investor Adviser/PMS/ Broking House. All the contents over here are for educational purposes only and are not investment advice or recommendations offered to any person(s) with respect to the purchase or sale of the stocks / futures and options. You are also requested to apply your prudence and consult your advisers in case you choose to act on any such content available as WE claims no responsibilities for any of your actions or any outcome of such action
NSE:JUBLPHARMA
by TrAder_3101_
JUBLPHARMANSE:JUBLPHARMA Please note that we are not a SEBI Registered Investor Adviser/PMS/ Broking House. All the contents over here are for educational purposes only and are not investment advice or recommendations offered to any person(s) with respect to the purchase or sale of the stocks / futures and options. You are also requested to apply your prudence and consult your advisers in case you choose to act on any such content available as WE claims no responsibilities for any of your actions or any outcome of such action
NSE:JUBLPHARMALong
by TrAder_3101_
Jubilant Pharmova Ltd : Looking for buyExpecting a potential upside of about 70%. They supply products and services to customers in over 85 countries. They have four manufacturing facilities in North America and two in India, coupled with Research and Development centres in North America and India. Additionally, they have a distribution network of more than 45 radiopharmacy in the United States. Leadership Positions Radiopharmaceuticals Third largest radiopharmaceutical manufacturer in the nuclear medicine industry in the United States based on revenue Second largest centralized commercial radiopharmacy network in the United States with a national footprint of more than 45 radiopharmacies across 22 states Allergy Therapy Products One of the top three players with a market share of 25% in the allergenic extract market in the United States and are currently the sole producer and supplier of venom products for the treatment of allergies in the United States APIs Among the leading global suppliers for several Key APIs. Solid Dosage Formulations One of the market leaders in the United States, based on the market share of several key products.
NSE:JUBLPHARMALong
by Sniper-Traders